Biomarker Solutions: Currently Available Assays
Biomarker Solutions: Currently Available Assays
Almac Diagnostic Services offer a range of DNA and RNA panel-based assays and single gene assays, from solid tissue and blood samples, across a range of technology and chemistry options.
Further technical information on these assays can be found utilising the appropriate links below.
If an assay that you are interested in is not represented in this current list, Almac are happy to discuss how we might support your biomarker programme needs with other commercially available assay solutions or help to customise an assay to your specific requirements.
Simply fill in the form below to get in touch.
HRD (Homologous Recombination Deficiency)
- Amoy Dx – HRD focus panel – INFO
- Illumina – TruSight™ Oncology 500 HRD – INFO
- SOPHiA Genetics – DDM HRD Solution – INFO
MSI (MicroSatellite Instability)
- Almac – WES MSI scoring – INFO
- Illumina – TruSight™ Oncology 500 – INFO
- Illumina – TruSight™ Oncology 500 ctDNA panel – INFO
- PGDx – elio ™ tissue complete – INFO
- PGDx – elio™ plasma resolve – INFO
- PGDx – elio™ plasma complete – INFO
- Promega – OncoMate™ MSI Dx Analysis System – INFO
TMB (Tumour Mutational Burden)
- Almac – WES TMB scoring – INFO
- Illumina – TruSight™ Oncology 500 – INFO
- Illumina – TruSight™ Oncology 500 ctDNA panel – INFO
- PGDx – elio™ tissue complete – INFO
- PGDx – elio™ plasma complete – INFO
RNA Gene Expression Assays
- Almac – claraT solution – INFO
- nanoString – Tumor Inflammation signature (TIS) – INFO
- nanoString – RUO PAM50 Breast Cancer Subtyping – INFO
- nanoString – Lymphoma Subtyping (LST) test – INFO
- Almac – Bespoke – INFO
MASH / MAFLD
Almac PNPLA3 – Clinical Trial Assay (CTA)
- Almac has developed and analytically validated a qPCR genotyping CTA to support allelic discrimination of PNPLA3 genotypes within whole blood and buccal swab samples, to identify patients homozygous or heterozygous for the PNPLA3 (rs738409) variants.
- The PNPLA3 Genotyping CTA was successfully developed and analytically validated for delivery from Almac’s UK and US CLIA laboratories. Almac has also successfully transferred the PNPLA3 Genotyping CTA to a partner laboratory within China.
MASH / MAFLD
Almac HSD17B13 – Clinical Trial Assay
- Almac has developed and analytically validated a kitted qPCR genotyping CTA to support allelic discrimination of HSD17B13 genotypes at the rs72613567 loci within whole blood and buccal swab samples, to identify patients homozygous or heterozygous for the HSD17B13 variants.
- The Almac HSD17B13 Genotyping CTA was successfully developed and analytically validated for delivery from Almac’s UK and US CLIA laboratories.
Almac R&D Assays
Almac Diagnostic Services also has extensive experience in the discovery and validation of clinically applicable gene expression biomarkers, through our own range of Almac proprietary R&D assays.
- Almac – DDIR (DNA Damage Immune Response) – INFO
- Almac – Angio – INFO
- Almac – EMT – INFO
- Almac – Prostate Dx – INFO
- Almac – Col Dx – INFO
For further information on any Almac R&D assays, please get in touch.